Neuroview Technology
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Neuroview Technology built an implantable neurodiagnostic device for long-term epilepsy monitoring. Its subcutaneous implant records continuous EEG data, transmitting it via smartphone to a cloud platform where analytics help clinicians detect unrecognized seizures, prevent mischaracterization of events, and optimize treatment — reducing the risk of seizure-related accidents and sudden death. Founded in 2016 in Englewood Cliffs, New Jersey, by Werner Doyle, Daniel Friedman, Ruben Kuzniecky, and Steven Pacia, the NYU-spinout company raised about $554,000 across angel, seed, and grant rounds and remained active.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Werner Doyle, Daniel Friedman, Ruben Kuzniecky, and Steven Pacia founded Neuroview Technology in Englewood Cliffs, New Jersey, to develop implantable epilepsy monitors.
- Angel funding
The company raised a $304,000 angel round while in pre-clinical development.
- Seed round
Neuroview Technology raised a $250,000 seed round, bringing total funding to about $554,000.
- Grant and accelerator
The company received a $75,000 grant and joined an accelerator while its device was in beta testing.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.